ANTICANCER RESEARCH 19: 2893-2900 (1999)
Qimin Zhan and Zheng Xu
Abstract: In the present study, we have investigated the effect of cytotrpic heterogeneous molecular lipid (CHML), a new anticancer agent, on growth suppression in a variety of human tumor cell lines. At a non-toxic concentration (a range from 25 ug/ml to 100 ug/ml), CHML has shown to strongly inhibit tumor cell growth by using a typical colony survival assay. At a treatment of concentration of 50 ug/ml for 6 hours, CHML is ale to suppress 50% of the tumor cell colony formation. At a concentration of 100 ug/ml (the therapeutic dosage in the clinical trial), more than 90% of the cells were killed in human breast carcinoma MCF-7, colorectal carcinoma RKO, kidney carcinoma G410, lung carcinoma and human myeloid leukemia ML-1 lines.
ANTICANCER RESEARCH 21:2477-2482 (2001)
Qimin Zhan, Shi-Cheng Zhao and Zheng Xu
Abstract: Cytotropic heterogeneous molecular lipid (CHML), which is a new anticancer agent with US patent number 5,260,067, has recently been shown to suppress tumor cell growth in multiple tumor lines and induce apoptosis in vitro (1). These results indicate that CHML may be an effective antitumor agent. In the present study, using both local injection and intravenous injection, we have investigated the suppressive effect of CHML on human breast cancer cells MCF-7 xenograft in nude mice.
Anticancer Research. 2007 May-Jun;27(3B):1593-600
Chen XC, Yu B, Dong JC , Gu YX, Chen L, Wu QZ , Hou NP, Liu JX, Xu JT, Jin RX, Jin GQ, Yang XD , Cao YW, Tan JJ, Zhu B, Shen JC , Xu Z, Varticovski L, Wang XW
Abstract: Hepatocellular carcinoma (HCC) and other forms of metastatic liver cancer (MLC) have poor outcomes due to the limited treatment options. Surgery, radiotherapy and chemotherapy have a limited success. Thus, there is an urgent need for novel therapies for patients with advanced HCC and MLC. The response and toxicity profile of a novel biological anticancer agent, cytotropic heterogeneous molecular lipids (CHML), in 135 Asian patients with hepatic malignancies treated at five different hospitals in China from April 1998 to August 2003 is described. This trial included 97 patients with HCC and 38 with MLC. The majority of these patients had received conventional therapies and many had failed to respond or relapsed. CHML was administered by intra-arterial ( i.a.) infusion with or without simultaneous intravenous (i.v.) infusion for 25 days with a rest of 2-4 weeks between each cycle. Fifty three percent of patients received two cycles, and 47% received three cycles. The complete response (CR) rates were 23% for HCC and 29% for MLC with an overall CR of 24%. The overall partial response (PR) was 53%. The patients with earlier stages and limited tumor burden had a better response, but a few patients with advanced disease also achieved PR. The patients who achieved CR or PR had a significant increase in long-term survival for up to five years. The treatment with CHML resulted in minimal toxicity and the reported adverse reactions were not higher than grade II. CHML is an effective therapy for hepatic malignancies, showing responses and increases in survival in patients in whom other therapies have failed. CHML is well tolerated and is an excellent candidate for Phase III clinical trials.
Chin J Clin Neurosci 2001
China Oncology 2002
Fudan University 2003
Chin J Clin Neurosci 2003
Chin J Ultrasonogr 2004
Journal of Tongji University (Medical Science) 2014